Compare AMPG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | MCRB |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 47.4M |
| IPO Year | 2012 | 2015 |
| Metric | AMPG | MCRB |
|---|---|---|
| Price | $3.40 | $5.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 2.2M | 58.5K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.44 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,195,930.00 | $789,000.00 |
| Revenue This Year | $102.41 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 164.99 | N/A |
| 52 Week Low | $1.64 | $4.32 |
| 52 Week High | $10.11 | $29.98 |
| Indicator | AMPG | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 48.84 |
| Support Level | $2.68 | $4.59 |
| Resistance Level | $4.15 | $5.65 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 9.40 | 72.46 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. It operates in two segments: the manufacturing and engineering segment. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.